Growth Hormone Deficiency Market Expected to Grow at a CAGR of 5.7% During 2025

Growth Hormone Deficiency Market Expected to Grow at a CAGR of 5.7% During 2025–2034, Says DelveInsight

The global growth hormone deficiency (GHD) market across the seven major markets (7MM) is projected to witness steady expansion during the 2025–2034 forecast period, registering a compound annual growth rate (CAGR) of 5.7%. Market growth is being driven by the emergence of innovative therapies such as LUM-201 and SCO-240, rising disease awareness, and continued improvements in diagnostic capabilities. Additional contributors include improved survival rates among premature infants, increasing incidence of pituitary disorders, and growing exposure to endocrine-disrupting environmental factors, all of which are fueling demand for growth hormone replacement therapies.

Growth hormone deficiency is a rare endocrine disorder characterized by inadequate secretion of growth hormone from the anterior pituitary gland. It may be congenital, acquired, or idiopathic in nature. Idiopathic GHD, in particular, remains challenging due to the absence of identifiable causes, underscoring persistent gaps in understanding disease biology and progression.

According to DelveInsight, approximately 207,000 prevalent cases of GHD were recorded across the 7MM in 2024, with nearly 165,000 diagnosed cases. This patient population is expected to increase steadily through 2034. The United States represented the largest share of diagnosed cases in 2024, accounting for nearly 70,000 patients, a number anticipated to grow further over the forecast period.

Stay ahead in the evolving GHD therapeutic landscape: https://www.delveinsight.com/report-store/growth-hormone-deficiency-ghd-market?utm_source=apac&utm_medium=pressrelease&utm_campaign=mpr

Current Treatment Growth Hormone Deficiency Market Landscape

The current GHD treatment landscape is dominated by recombinant human growth hormone (rhGH) therapies, including long-acting agents such as SOGROYA, SKYTROFA, and NGENLA. While long-acting formulations have reduced injection frequency, many patients—particularly children—continue to face adherence challenges due to the injectable nature of therapy and needle-related anxiety.

SOGROYA (somapacitan-beco) is a long-acting human growth hormone analog approved for both pediatric and adult GHD. It mimics endogenous GH activity by activating GH receptors and stimulating insulin-like growth factor-1 (IGF-1) production. Regulatory approvals span the US, EU, and Japan between 2020 and 2023.

SKYTROFA (lonapegsomatropin-tcgd), a once-weekly pegylated GH therapy, is approved in the US and EU for pediatric GHD. It delivers sustained GH exposure and supports growth and metabolic regulation via IGF-1–mediated pathways. An FDA sBLA for adult GHD was accepted in December 2024, with a regulatory decision expected in mid-2025.

NGENLA (somatrogon-ghla) is another once-weekly GH analog approved globally for pediatric GHD. It activates GH receptors and STAT5b signaling to elevate IGF-1 levels and promote linear growth. Phase III clinical trials for adult GHD are ongoing, positioning the therapy for potential indication expansion.

Access DelveInsight’s comprehensive @ Growth Hormone Deficiency Market Report

Growth Hormone Deficiency Emerging Therapies and Innovation Focus

To further address adherence limitations associated with injectable therapies, drug developers are increasingly prioritizing oral agents and advanced long-acting platforms.

LUM-201 (ibutamoren), developed by Lumos Pharma, is an oral GH secretagogue receptor agonist that stimulates the body’s natural pulsatile GH secretion. Phase II OraGrowtH210 and OraGrowtH212 trials demonstrated favorable safety and efficacy in pediatric GHD. The drug holds orphan drug designation in both the US and EU, and 24-month data presented in late 2024 confirmed sustained growth benefits.

SCO-240, an oral small-molecule SSTR5 antagonist from SCOHIA PHARMA, has shown promising Phase I results by selectively enhancing GH secretion without disrupting other pituitary hormones. The therapy demonstrated good tolerability and suitability for once-daily dosing and has received support under Japan’s AMED orphan drug development program.

Evaluate strategic opportunities in the global @ Growth Hormone Deficiency Market Forecast

Asia-Focused Development

Japan continues to play a critical role in the regional GHD clinical landscape. Teijin Pharma holds exclusive rights in Japan for Somavaratan, a long-acting rhGH analog originally developed by Versartis. Teijin is responsible for local development, regulatory execution, and commercialization and is currently overseeing late-stage Phase II/III programs across pediatric and adult GHD populations. These efforts reflect Japan-specific regulatory alignment and sustained local development activity.
Additionally, Ascendis Pharma’s TransCon™ hGH (lonapegsomatropin)—already approved in several global markets—has conducted Phase III trials registered within Japan’s jRCT system. These trials are significant for supporting future Japanese regulatory filings despite Ascendis being headquartered outside Asia.
South Korea represents one of the most active Asian markets for GHD clinical development. Genexine Co., Ltd. is advancing eftansomatropin alfa (GX-H9 / TJ101), a long-acting GH analog utilizing its proprietary hyFc® fusion platform to enable once-weekly dosing.
Phase II studies in pediatric GHD established safety and dose parameters, while a multinational Phase III pivotal study successfully met its primary endpoint, demonstrating non-inferiority to daily somatropin in terms of annualized height velocity. Based on these results, Genexine’s partner I-Mab submitted a Biologics License Application in China in 2024, highlighting the program’s advanced regulatory trajectory.
At present, no Taiwan-based biotechnology or pharmaceutical companies have been identified as sponsors of active interventional clinical trials for GHD therapies. While Taiwan maintains strong capabilities in manufacturing and CDMO services, local companies currently do not appear to be directly engaged in late-stage therapeutic GHD development.

Download the @ Growth Hormone Deficiency Market Forecast

Growth Hormone Deficiency Market Outlook

DelveInsight estimates that the growth hormone deficiency market across the 7MM was valued at approximately USD 1.4 billion in 2024 and is expected to grow at a CAGR of 5.7% through 2034. Market expansion will be supported by increasing prevalence, enhanced diagnostic accuracy, expanding access to long-acting and oral therapies, and strong late-stage pipelines in both Western and Asian markets.

DelveInsight’s Growth Hormone Deficiency Market Insight, Epidemiology, and Market Forecast – 2034 provides comprehensive analysis across epidemiology, treatment guidelines, patient segmentation, and competitive dynamics. With continued innovation, favorable regulatory momentum, and improving patient compliance solutions, the GHD market is poised for significant transformation over the next decade.

Growth Hormone Deficiency Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted GHD epidemiology in the 7MM, i.e., the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.

Growth Hormone Deficiency Pipeline

Growth Hormone Deficiency Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GHD companies, including Novo Nordisk, Ascendis Pharma, among others.

Adult Growth Hormone Deficiency Market

Adult Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key adult growth hormone deficiency companies, including Novo Nordisk, Ascendis Pharma, among others.

Pediatric Growth Hormone Deficiency Market

Pediatric Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pediatric growth hormone deficiency companies, including TJ Biopharma, Lumos Pharma, SCOHIA PHARMA, Inc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

+14699457679